June 2, 2017

Myriad Announces 17 Additional Health Insurance Plans Covering EndoPredict™

Coverage Decisions Add 35 Million Additional Covered Lives Bringing Total to 109 Million

SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that multiple new insurance plans have announced positive coverage policies for EndoPredict. Recently, Blue Shield of California, Humana, Inc., and multiple regional plans announced positive coverage decisions for the test.

Additionally, Highmark Blue Cross Blue Shield, Independence Blue Cross, and Health Care Service Corporation have posted positive coverage policies which take effect in July 2017. Combined, these plans represent greater than 35 million additional covered lives for EndoPredict and in aggregate, private plans representing 109 million covered lives, now have positive coverage policies on EndoPredict.

Furthermore, on May 4, 2017 Palmetto GBA, which runs the MolDx program for the Centers for Medicare and Medicaid Services (CMS) posted a positive draft local coverage determination (LCD) for EndoPredict. If this draft LCD is approved, combined with the current private coverage for the test, EndoPredict would be covered for approximately 75 percent of breast cancer patients in the United States.

"The ramp in coverage for EndoPredict has been extremely rapid and we are very close to having nearly full coverage for this important test," said Mark C. Capone, president and CEO, Myriad Genetics. "We believe this unprecedented ramp in coverage is reflective of the strong data including the head-to-head study which showed that EndoPredict "markedly outperformed" the first-generation test in breast cancer patients."

About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Highmark Blue Cross Blue Shield, Independence Blue Cross, and Health Care Service Corporation positive coverage policies taking effect in July 2017; EndoPredict being covered for approximately 75 percent of breast cancer patients in the United States if the draft LCD is approved and combined with the current private coverage for the test; the Company being very close to having nearly full coverage for EndoPredict; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets

for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Ron Rogers
(801) 584-3065
rrogers@myriad.com

Investor Contact: Scott Gleason
(801) 584-1143
sgleason@myriad.com